Baxter International Inc

BAX: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$41.00BzfmqmqDpzvwsd

Baxter Earnings: Legacy Hill Rom Woes Overshadow Rising Medical Utilization and 2024 Outlook

Narrow-moat Baxter turned in strong first-quarter results, and management raised its expectations for 2024 on those trends. However, a mild increase to our near-term expectations does not materially change our $67 fair value estimate. Shares remain steeply undervalued, in our opinion, and May 2's share decline appears related to disappointment that the legacy Hill Rom assets constrained this quarter's results that were otherwise strong on rising medical utilization and a cooling inflationary environment.

Sponsor Center